HER-2/neu is a candidate for developing breast cancertargeted immunotherapeutics. Although DNA-based and HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity, there has been no side-by-side study comparing them directly. The present study utilizes an in vivo murine tumor model expressing HER-2/neu antigen to compare the efficacy between adenovirus (AdVneu)-transfected dendritic cells (DC neu ) and plasmid DNA (pcDNAneu) vaccine. Our data showed that DC neu upregulated the expression of immunologically important molecules and inflammatory cytokines and partially converted regulatory T (Tr)-cell suppression through interleukin-6 (IL-6) secretion. Vaccination of DC neu induced stronger HER-2/neu-specific humoral and cellular immune responses than DNA vaccination, which downregulated HER-2/neu expression and lysed HER-2/neupositive tumor cells in vitro, respectively. In two HER-2/ neu-expressing tumor models, DC neu completely protected mice from tumor cell challenge compared to partial or no protection observed in DNA-immunized mice. In addition, DC neu significantly delayed breast cancer development in transgenic mice in comparison to DNA vaccine (Po0.05).
Introduction
The rat neu gene was originally identified in rat neuroblastomas in the early 1980s and is a protooncogene encoding a 185 kDa protein with homology to the epidermal growth factor receptor (EGFR) family. 1 The proto-oncogene HER-2 is the human analog and shares greater than 85% amino-acid sequence homology to the rat neu. 2 HER-2/neu is a transmembrane protein consisting of a cysteine-rich extracellular domain (ECD) that function in ligand binding and an intracellular domain (ICD) with kinase activity. The HER-2/neu gene has been found to be amplified and/or overexpressed in numerous human malignancies such as ovarian and gastric carcinomas, and particularly in approximately 25-30% of breast cancers in humans, most commonly in invasive ductal carcinomas. 3 Patients with HER-2/neupositive tumors are less responsive to chemotherapy and have a poor prognosis. 4 Studies of patients with HER-2/ neu-expressing tumors have demonstrated the existence of humoral and T-cell responses against the HER-2/neu antigen (Ag), 5 although insufficient to prevent tumor outgrowth. The existence of antibodies and T cells reactive to HER-2/neu was first reported in patients with breast cancer whose tumors overexpressed HER-2/ neu. 6 Since then, a number of other studies have also documented the presence of these endogenous immune responses, both humoral 5 and cellular, 7 against HER-2/ neu. The existent immune responses to HER-2/neu, although they are of low magnitude, indicate that HER-2/neu is an immunologic target and a suitable candidate for HER-2/neu-targeted vaccine strategies.
Naked DNA vaccination is an efficient means for induction of antigen-specific immunity. 8 DNA-based vaccines involve the direct inoculation of expression plasmids into the hosts. It presents several potential advantages, when compared to more conventional vaccination strategies, such as (i) multiple Ag in a single vaccine, (ii) its large scale production and (iii) cheaper storage. 8 Genetic DNA vaccines using plasmid DNA expressing ECD along with the transmembrane domain and complete HER-2/neu have been reported to induce both HER-2/neu-specific humoral and T-cell immune responses. 9 The antitumor immune responses induced by DNA vaccines could protect mice from challenge of HER-2/neu-positive tumor cells 10, 11 and partially reduce tumor development in rat HER-2/neu-gene transgenic mice. [12] [13] [14] Insertion of interleukin (IL)-1b sequence 15 or co-administration of genetic adjuvants 16, 17 or primeboost vaccination with plasmid DNA and adenovirus gene therapy 18 all induced enhanced antitumor immunity. However, these approaches still did not induce any therapeutic effects even with in vivo DNA electroporations. 19 In principle, dendritic cells (DCs) exert a predominant role in DNA vaccination, although other tissues may also capture the injected DNA and express the encoded protein. 20 DCs, which represent powerful antigen-presenting cells (APC), are derived from bone marrow (BM) monocyte populations. 21 Because of the critical role DCs have in the induction of primary immune responses, they have been extensively used for cancer vaccines. DCbased vaccine starts with the use of DCs pulsed with the tumor-derived major histocompatibility complex (MHC) class I-restricted peptides. 22 The complexes of MHC class I and tumor peptides on DCs are recognized by the T-cell receptor (TCR) of CD8 + T cells, leading to activation and differentiation to cytotoxic T lymphocytes (CTL). DCs pulsed with MHC class I-restricted HER-2/neu tumor peptide were able to induce CTL-dependent antitumor immune responses in vitro and in vivo. 2, 23 As CD4 + helper T (Th) cells triggered by the complexes of MHC class II and tumor peptide on DCs play an important role in facilitating antitumor immunity by augmentation of the CTL responses, 24 DCs have been engineered to express HER-2/neu Ag containing both MHC class I-and IIrestricted tumor peptides. 25, 26 It has been demonstrated that these engineered DCs can elicit both HER-2/neuspecific CTL and Th clones 27 and stimulate antitumor immunity against challenge of HER-2/neu-positive tumor cells in vivo, 25, 26 leading to phase I/II clinical trials. 28 However, there are limited studies evaluating the use of HER-2/neu-targeted DC-based vaccination in rat HER-2/neu-gene transgenic mice with self HER-2/neu tolerance. 29 Although both naked DNA-based and gene-modified DC-based vaccines are potent at eliciting HER-2/neuspecific antitumor immunity, there has been no side-byside comparison of the efficacy for these two kinds of vaccines. In this study, we constructed an expression vector pcDNAneu and an adenoviral (AdV) vector AdVneu, both expressing the rat HER-2/neu Ag for DNA-based and AdVneu-engineered DC vaccines, termed DC neu , respectively. We investigated and compared the efficacy of HER-2/neu-specific antitumor immunity in both wild-type and transgenic animal models using these two vaccination methods. In addition, the mechanisms of immunity involved in these vaccinations were also elucidated.
Results

HER-2/neu expression of MCA-26neu and DC neu cells
The mouse breast cancer cell line Tg1-1 overexpresses cell-surface rat HER-2/neu Ag, herein referred to as neu, as detected by flow cytometry using the anti-neu Ab. In contrast, the mouse colon cancer cell lines CaD1, MCA-26 and bone-marrow (BM)-derived DCs do not ( Figure   1a ). We constructed the expression vector pcDNAneu and the adenoviral vector AdVneu, both expressing rat neu. We then generated the transfected MCA-26neu tumor cell line and the gene-modified DC neu cells by using pcDNAneu and AdVneu, respectively. As shown in Figure 1a , both MCA-26neu and DC neu exhibited expression of neu Ag as did Tg1-1 cells. To confirm neu expression, Western blot analysis using protein extracts of the above six types of cells were examined for neu expression. As shown in Figure 1b , Tg1-1, MCA-26neu and DC neu cells displayed significant amount of neu Ag expression (185 kD), whereas CaD1, MCA-26 and DCs did not express any neu molecule.
DC neu cells upregulate expression of immunologically important molecules, cytokines and chemokines
We then analyzed the impact of AdV transfection on the expression of various cell-surface molecules. As shown in Figure 2a , transfection of AdVneu led to a mild to moderate upregulation of MHC class II, CD40, CD54 and CD80 expression on DC neu cells, relative to the untreated DCs, indicating that these DC neu cells became a more mature form of DCs. The expression of MHC class I, CD11b, CD11c and CD86 remained unchanged on these DCs (data not shown). Transfection of the control AdVpLpA also led to a mild or moderate upregulation of MHC class II, CD40, CD54 and CD80 expression on DC pLpA cells (data not shown) as did DC neu , indicating that the upregulation of MHC class II, CD40, CD54 and CD80 expression was derived from AdV transfection of DCs itself. In addition, we also found that DC neu upregulated the expression of inflammatory cytokines (IL-1b, tumor necrosis factor alpha (TNF-a) and IL-6), chemokines (IP-10 and MIP-1b) and the chemokine receptor (CCR7), compared to the untransfected DCs Western blot analysis. Protein extracts were obtained from the above cell lines and loaded onto a polyacrylamide gel under reducing conditions. Transferred nitrocellulose paper strips were incubated with mouse anti-neu Ab followed by peroxidaseconjugated goat anti-mouse IgG Ab. Detection of neu expression was accomplished using enhanced chemiluminescence reagent.
Comparing HER-2/neu DNA and engineered DC vaccines T Chan et al ( Figure 2b ). The secretion of IL-6 and TNF-a was further estimated to be around 650 pg/ml and 400 pg/ml for DC neu and minimal concentrations of 0 pg/ml and 30 pg/ml for DCs, respectively (Figure 2c ).
DC neu induce much stronger Th1-type immune response than pcDNAneu
Tumor rejection and growth has been shown to be associated with interferon gamma (IFN-g) and immunoglobulin (Ig) G2a dominant Th1 and IL-4 and IgG1 dominant Th2-type immune response, respectively. 30 To investigate the type of immune response derived from DC neu and DNA vaccines, supernatants of lymph node (LN) T cells from immunized mice were examined for cytokine secretion using cytokine enzyme-linked immunosorbent assay (ELISA) kits. In response to irradiated Tg1-1 cells, regional LN T cells from mice immunized with DC neu or pcDNAneu predominantly secreted IFN-g, but not IL-4, indicating a Th1-type immune response. However, the former ones secreted much higher IFN-g (1200 pg/ml) than the later ones (180 pg/ml) (Figure 2c ), indicating that DC neu vaccine induces a much stronger Th1-type immune response than DNA vaccine.
DC neu partially convert CD4 + 25 + Tr suppression by IL-6 secretion It has recently been reported that the inflammatory cytokine IL-6 is required for T-cell activation in vivo and can convert regulatory T (Tr)-cell-mediated immune tolerance. 31 Since our AdVneu-transfected DC neu expressed IL-6, we examined whether they can also convert the CD4 + 25 + Tr-mediated immune suppression. We conducted T-cell proliferation assay by using DC neu in the presence of Tr cells. As shown in Figure 3a Comparing HER-2/neu DNA and engineered DC vaccines T Chan et al DC neu vaccine stimulates stronger HER-2/neu-specific humoral response than DNA vaccine
To examine whether neu-targeted vaccines induce neuspecific humoral response, FVB/N mice were vaccinated with DC neu and pcDNAneu DNA, and sera were collected 2 weeks after each vaccination. The presence of HER-2/neu-specific IgG1 and IgG2a antibodies (Abs) was assessed by flow cytometric analysis on Tg1-1 cells incubated with mouse sera, followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG1 and IgG2a Abs, respectively. As shown in Figure 4a , neuspecific IgG2a but not IgG1 response was stimulated in mice vaccinated with DC neu once, indicating a neuspecific Th1-type response. Both IgG1 and enhanced IgG2a were detected in sera of mice vaccinated with DC neu twice, indicating that both Th1-and Th2-type responses were stimulated after the boost. In contrast, a very slight increase of IgG2a Ab binding was only detected in mice vaccinated with DNA twice, confirming a mild induction of a Th1-type response. No neu-specific Abs were detected in sera of unvaccinated mice (data not shown). To confirm the above results, the presence of neu-specific IgG1 and IgG2a Abs was also assessed by live cell ELISA using Tg1-1 cells grown in 96-well plates and serum samples incubated on the plates, followed by peroxidase-conjugated goat anti-mouse IgG1 and IgG2a Abs, respectively. As shown in Figure 4b , mice vaccinated twice with DC neu induced stronger neu-specific IgG2a and IgG1 Ab responses, whereas vaccination of mice with pcDNAneu twice only stimulated a mild HER-2/neu-specific IgG2a Ab response.
DC neu -derived neu-specific antibody induces downregulation of HER-2/neu expression and inhibits growth of Tg1-1 tumor cells
Previous studies have shown that the antibodies recognizing neu induced neu downregulation and growth inhibition of tumor cells. 32 As shown in Figure 5a , incubation of Tg1-1 cells with sera from DC neu -immunized mice resulted in an apparent downregulation of HER-2/neu expression in Tg1-1 cells. As HER-2/neu expression is related to tumor cell growth, we then examined whether the presence of anti-neu Abs affected Tg1-1 cell proliferation in vitro. As shown in Figure 5b , the sera from DC neu -immunized mice clearly inhibited B73% of TG1-1 cell growth in vitro after 5 days, compared to cells incubated with sera from phosphatebuffered saline (PBS)-vaccinated mice (Po0.0001). The serum from DNA-immunized mice also resulted in B38% inhibition of Tg1-1 proliferation (Po0.005 in comparison to PBS) but the serum from DC neu -immunized mice clearly had a greater growth inhibitory effect (between DC neu and DNA sera, Po0.005). In addition, the neu Ab also resulted in B58% growth inhibition. Meanwhile, sera from the immunized mice did not inhibit growth of HER-2/neu-negative CaD1 tumor cells, indicating that the growth inhibition is neu-specific (data not shown).
DC neu vaccine stimulates stronger HER-2/neu-specific CTL response than DNA vaccine Next, we addressed the specific antitumor effector function induced by vaccination of the mice with DC neu Comparing HER-2/neu DNA and engineered DC vaccines T Chan et al and pcDNAneu DNA. Spleen lymphocytes from immunized mice were cocultivated with irradiated Tg1-1 tumor cells for 3 days and activated T cells were harvested. To assess the cytotoxic activity, we conducted a chromium release assay using activated T cells as effectors cells and 51 Cr-labelled Tg1-1 tumor cells as target cells. As shown in Figure 6a , activated T cells from mice vaccinated with DC neu showed significant killing activity to Tg1-1 cells. At an effector:target (E:T) ratio of 50, the specific killing activity for activated T cells from mice with vaccination of DC neu was 36%, which is much higher compared to the 12% killing activity for activated T cells from DNA-vaccinated mice. This CTL activity was immunologically specific as T cells from the mice vaccinated with uninfected DCs had only little activity against the Tg1-1 (data not shown). Similar levels of in vitro killing were also observed in the in vivo cytotoxicity assay, where carboxyfluorescein diacetate succinimidyl ester (CFSE) high (neu peptide pulsed)-and CFSE low (irrelevant peptide)-labeled cells were transferred into DNA and DC neu -immunized mice. The disappearance of labeled cells was examined by flow cytometric analysis. Levels of CFSE low cells remained relatively unaffected, whereas the levels of CFSE high in DNA-immunized mice decreased slightly by 8%. However, a greater degree of loss of CFSE high cells (B40%) from DC neu -immunized mice was observed.
DC neu vaccine induces more efficient protective tumorspecific immunity than DNA vaccine in wild-type mouse models
To examine whether the neu-targeted vaccines were capable of inducing antitumor immunity in vivo, we vaccinated wild-type FVB/N mice twice with DC neu and pcDNAneu DNA, then challenged 10 days later with 3 Â 10 5 Tg1-1 tumor cells. As shown in Figure 7a , Tg1-1 tumor cell challenges were invariably lethal within 6 weeks post-implantation for the control DC pLpA -vaccinated mice. Vaccination of mice with DC neu twice had stronger antitumor immunity, with all mice protected from challenge of 3 Â 10 5 Tg1-1 tumor cells and remained tumor free at the end of the study, whereas only half of the mice (4/8) mice given two DNA vaccinations remained tumor free (Po0.05). These data indicate that DC neu vaccination induces more efficient protective tumor-specific immunity in vivo than DNA vaccination.
To confirm the above finding, we repeated the study using a MCA-26neu animal model. We vaccinated wildtype BALB/c mice twice with DC neu and pcDNAneu DC neu vaccine delays breast cancer development significantly longer than DNA vaccine in transgenic mouse model
To determine whether the antitumor immunity derived from HER-2/neu-targeted vaccines can inhibit carcinogenesis, we vaccinated FVBneuN transgenic mice at age 2 and 4 months, time periods representing atypical hyperplasia and infiltrating ductal carcinomas, respectively, with DC neu cells and pcDNAneu DNA at 1 month intervals for a total of three times, respectively. Agematched controls were also used to monitor spontaneous breast tumor development. As shown in Figure 8 , transgenic mice immunized with DC neu at age of 2 months (Po0.05), but not at age of 4 months, had a significant delay in tumor development compared to that of the DNA-immunized mice. Our data again indicated that DC neu -based vaccination induced stronger neuspecific preventive immunity in transgenic mice than DNA vaccination.
Discussion
It was originally reported that plasmid DNA encoding a truncated rat neu lacking the ICD could induce antitumor immunity that was as strong as the one induced by the plasmid encoding the full-length HER-2/ neu. 33 Evidence from clinical trials, however, demonstrated that CD4 + T cells derived from peptide vaccine recognized peptide epitopes from both ECD and ICD of HER-2/neu, 5, 34 suggesting that ICD may represent a better immune target given its limited exposure to the external environment. In support of this assumption, it has been shown that only vaccination with DNA encoding ICD or ICD protein of HER-2/neu can elicit antitumor immunity, but not with DNA encoding ECD or ECD protein. 11, 35 More recently, it has also been reported that the antitumor immunity derived from vaccination of DNA encoding ICD of HER-2/neu was mediated by HER-2/neu-specific CTL, but not humoral response. 36, 37 Conceptually, vaccination with DNA en- Previous reports have shown that AdV transfection itself can mature DCs. 38, 39 In this study, our data also showed that the transfected DC neu upregulated the expression of immunologically important molecules (MHC class II, CD40, CD54 and CD86) and inflammatory cytokines (IL-6, TNF-a, IL-1b, macrophage inflammatory protein-beta (MIP-b) and IP-10), compared with the untransfected DCs, indicating that AdV-transfected DCs are more immunogenic form of DCs with high immunostimulatory properties and capability in stimulating both natural killer cells and CTL. 39 For example, IL-6 is required for T-cell activation and can convert Trmediated immune suppression. 31 TNF-a is an immunoregulatory cytokine with the ability to activate both T cells 40 and DCs 41 and to ameliorate IL-10-mediated DC inhibition. 42 The chemokines MIP-b and IP-10 expressed by DC neu are each chemotactic for T cells and DCs. 43 Therefore, upregulation of the above cytokines and chemokines may play some role in DC neu -induced anti-HER-2/neu immunity.
In this study, our results also demonstrated that mice immunized with DC neu and pcDNAneu predominantly secreted IFN-g, but not IL-4 indicating induction of a Th1 immune response. However, the T cells from DC neuimmunized mice secreted much higher IFN-g than the T cells from pcDNAneu-immunized mice, which allows for class switching and accounts for higher levels of HER-2/neu-specific IgG2a than IgG1 Ab, confirming a Th1-type response. Moreover, we show that immune sera containing anti-neu Ab from mice immunized with DC neu also downregulated HER-2/neu expression, which has been reported with the use of the humanized anti-HER2 Ab Herceptin, 44 and inhibited the growth of Tg1-1 tumor cells to a greater degree than the sera from DNA-immunized mice. In addition, DC neu vaccination stimulated stronger neu-specific CTL responses than pcDNAneu DNA vaccine. The activated T cells from mice vaccinated with DC neu showed significant neu-specific killing of 36% (at E:T of 50) to Tg1-1 cells, compared with only 12% killing activity derived from activated T cells of mice with vaccination of pcDNAneu DNA. This CTL activity is immunologically specific, in as much as none of these populations showed cytotoxic activities against the neu-negative CaD1 tumor cells. Similar degree of cytotoxicity was observed in the in vivo cytotoxicity assays, which is consistent with a report by Murata et al. 45 that showed low to modest cytotoxicity activity in mice using this highly sensitive assay. More importantly, vaccination of DC neu cells stimulated significant anti-neu immunity in vivo, which protected all mice from challenge of Tg1-1 tumor cells expressing the rat neu Ag in wild-type FVB/N mice, whereas DNA vaccine only protected 50% of mice from Tg1-1 tumor cell challenge, indicating that DC neu vaccine induced much stronger neu-specific immunity than pcDNAneu DNA vaccine. This conclusion has been confirmed by using another wild-type mouse MCA-26neu tumor model. Vaccination of DC neu cells also resulted in tumor protection in 8/8 mice, whereas none of mice vaccinated with pcDNAneu rejected MCA-26neu expressing the HER-2/neu Ag.
The FVBneuN transgenic mice were derived from the parental FVB/N strain and express the wild-type rat HER-2/neu cDNA under the control of a mouse mammary tumor virus promoter. 46 Female mice spontaneously and stochastically develop mammary tumors in situ and small mammary tumors beginning at 2 and 4 months of age, respectively. 47 Because the HER-2/neu tumor Ag is endogenous to the host, this allows for development of tolerance to the self HER-2/neu Ag, as evidenced by the poor ability of these mice to develop HER-2/neu-specific antitumor immunity following vaccination as compared with the parental FVB/N mice. 48 Therefore, this mouse model of breast cancer that closely mimics immune tolerance described in some patients with cancer 14 becomes suitable for evaluating HER-2/ neu-targeted vaccines. In this study, we demonstrated that DC neu vaccinations starting at 2 months of age could delay breast cancer development significantly longer in transgenic mice than DNA vaccine, indicating that AdVmediated HER-2/neu-gene-engineered DC vaccine is superior to DNA vaccination in breast cancer prevention of transgenic mice. However, there were no cases of complete prevention of breast cancer development observed in DC neu -immunized transgenic mice. The relative low efficiency of DC neu -induced immunity in transgenic mice is probably owing to the HER-2/neuspecific self immune tolerance. 29 Furthermore, regardless of the vaccine used to immunize mice beginning at 4 months of age, spontaneous tumor development in DC neu -immunized was comparable to both DNA-immunized and age-matched controls. The delay observed when immunizing mice with DC neu at a younger age may have been a result in the early generation of an effective immune response against neu but over time, the immune response declines in the presence of clinical tumors overexpressing neu. 49 This indicates that the efficiency of HER-2/neu-targeted DC-based vaccination needs further improvement. Furthermore, vaccination of DCs engineered by two different AdV to express two transgenes such as HER-2/neu and TNF-a 26 or IL-12 25 has shown augmented anti-HER-2/neu immunity than DCs engineered to express only HER-2/neu. Therefore, DCs engineered to express both tumor Ag and cytokine genes may represent a new direction in DC-based vaccine. These engineered DC vaccines may be assessed in a therapy model, which would be more relevant to clinical application. The reduced efficacy pcDNAneu DNA vaccine in generating anti-HER-2/neu immunity compared to DC neu vaccine may be derived from the following reasons. As indicated above, immunization using naked DNA relies on the uptake of DNA by host APC. 20, 50 Defective APC function in situ has been documented in tumor-bearing mice and may in part explain the failure in induction of effective immunity using naked DNA in these studies. 51, 52 Secondly, it has also been reported that, in general, DNA vaccine, although inducing antitumor Comparing HER-2/neu DNA and engineered DC vaccines T Chan et al CTL responses, often failed in breaking immune tolerance in animal models. 13 Another important factor may stem from the reduced number of vaccination/boosts with the DNA used in our study compared to other reports. 9, 10 Taken together, we have demonstrated that AdVmediated HER-2/neu-gene-modified DC vaccine is more potent than DNA vaccine in both protective and preventive animal tumor models in our side-by-side comparison study. Therefore, DCs genetically engineered to express tumor antigens such as HER-2/neu are likely representative of a new direction in DC-based vaccine of breast cancer.
Materials and methods
Cell lines, antibodies, cytokines and animals
A mouse breast cancer cell line TG1-1 (H-2K q ), 9 derived from a spontaneous breast cancer of transgenic FVBneuN mouse, was obtained from Dr T Kipps, University of California, San Diego, CA, USA. The mouse colon cancer cell line MCA-26 (H-2K d ) was obtained from American Type Culture Collection (ATCC; Rockville, MD, USA). A mouse mammary carcinoma cell line CaD1 (H-2K q ) was obtained from Frederick Cancer Research and Development Center (Frederick, MD, USA). These cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (GIBCO, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS). 293 cell line (adenoviral E1-transformed human embryonic kidney cells) was also obtained from ATCC and maintained in minimum essential medium with Earle's salts (EMEM) (GIBCO) supplemented with 10% FCS. Monoclonal rat anti-mouse H-2K q Ia q H-2K d Ia d CD11b, CD11c, CD40, CD54, CD80 and CD86 antibodies (Abs) were all purchased from BD Pharmingen (San Diego, CA, USA). Anti-rat HER-2/neu Abs (Ab-3, Ab-4) were purchased from Oncogene (San Diego, CA, USA). Biotin-labeled anti-mouse IgG1 and IgG2a antibodies were purchased from Caltag Laboratories (Burlingame, CA, USA). FITCconjugated goat anti-rat IgG and anti-mouse IgG, FITCconjugated streptavidin and streptavidin-peroxidase Abs were purchased from Jackson ImmunoResearch (LabsWest Grove, PA, USA). Recombinant mouse granulocyte macrophage colony stimulation factor (GM-CSF) and IL-4 were purchased from Endogen (Woburn, MA, USA) and R&D Systems Inc. (Minneapolis, MN, USA) , respectively. Wild-type female FVB/N (H-2K q ), transgenic female FVBneuN (H-2K q ) and wild-type female BALB/c (H-2K d ) mice were obtained from Jackson laboratory (Bar Harbor, ME, USA). All mice were housed in the animal facility at the Saskatoon Cancer Centre, and experiments were approved by the University Committee on Animal Care and Supply, in accordance with Canadian Council for Animal Care guidelines.
Expression vector pcDNAneu
The complete length of rat HER-2/neu gene fragment 53 was obtained from Dr R Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA, USA. The expression vector pcDNAneu was constructed by cloning the HindIII/KpnI rat neu DNA fragment into pcDNA plasmid (Invitrogen, Carlsbad, CA, USA). Endotoxin free DNA was purified using Qiagen Endo-free Giga kits (Qiagen, Mississauga, Ontario, Canada), according to the manufacturer's instructions. Purified DNA was resuspended in sterile PBS at a final concentration of 1 mg/ml and stored at À201C until use.
Transfection of MCA-26 tumor cell line
MCA-26 cell were transfected with the expression vector pcDNAneu as previously described. 26 Briefly, twenty million MCA-26 cells were resuspended in 0.7 ml PBS and mixed with 0.3 ml PBS containing 10 mg pcDNAneu DNA. Tumor cells were transfected via electorporation using a Gene Pulser (BioRad, Richmond, CA, USA) with parameters of 300 V and 125 mFD capacitance. Transfected cells were selected for growth in medium containing 4 mg/ml G418 (Geneticin; GIBCO). The selected clone MCA-26neu was maintained in growth medium containing 0.5 mg/ml G418 and expression analyzed by flow cytometry and Western blotting.
Recombinant adenovirus AdVneu
The recombinant adenoviral plasmid was constructed by using the AdEasy System (Stratagene, La Jolla, CA, USA). Briefly, the KpnI/EcoRV rat neu DNA fragment was ligated into pShuttleCMV, forming pShuttleCMVneu. The shuttle vector was then co-transformed with the backbone vector, pAdEasy-1, into BJ5183 Escherichia coli cells for homologous recombination to form the adenoviral (AdV) vector. The recombinant AdV vector was then transfected into 293 cells using Lipofectamine (GIBCO), according to the manufacturer's protocol, to generate AdVneu. The control AdVpLpA (i.e., with no gene insert) was previously constructed in our laboratory. 54 All of the E1/E3-deleted replicationdeficient recombinant AdV, under the control of the cytomegalovirus (CMV) early/immediate promoter/enhancer, were amplified in 293 cells and purified by a series of cesium chloride ultracentrifugation gradients and stored at À801C.
Preparation of BM-derived DCs
BM-derived DCs were prepared as described previously. 26 Briefly, BM cells prepared from femora and tibiae from FVB/N and BALB/c mice were depleted of red blood cells with 0.84% Tris-ammonium chloride and plated in DC culture medium (DMEM plus 10% FCS, GM-CSF (20 ng/ml) and IL-4 (20 ng/ml)). Nonadherent granulocytes, T and B cells were gently removed and fresh media were added on the third day. After 2 days, loosely adherent proliferating DC aggregates were dislodged and replated. Nonadherent cells were harvested on the sixth day and DCs generated in this manner were displayed: (i) typical morphologic features of DCs (i.e., numerous dendritic processes) and (ii) expression of MHC class I (H-2K q or H-2K d ) and II (Ia q or Ia d ), co-stimulatory (CD40 and CD80) and adhesion (CD54, CD11b and CD11c) molecules (data not shown). These well-differentiated mature DCs were then used for in vitro AdVneu transduction.
Adenoviral transduction of DCs
In general, nonviral DNA transfection methods are inefficient, particularly in nondividing cells, as there is only very limited DNA trafficking to the nucleus where transcription occurs. 55 It has been reported that the transfection efficiency using in vitro activated, BMComparing HER-2/neu DNA and engineered DC vaccines T Chan et al derived well-differentiated mature DCs with plasmid DNA by electroporation was very limited. 56, 57 AdV vector-mediated transfection is commonly used for gene transfer. 58 It has been shown that AdV-mediated gene transfer of DCs is much more efficient than plasmid DNA-mediated gene transfer by electroporation. 59 Therefore, we selected to compare AdV-transfected DCs with plasmid DNA in this study. DCs were transduced with AdVneu and AdVpLpA at an optimal multiplicity of infection (MOI) of 100, as previously described, 26 and termed DC neu and DC pLpA , respectively. To enact this, following viral adsorption for 1 h at 371C in DMEM in six-well culture plates, DC culture medium was replaced with DMEM containing 20% FCS. The cells were incubated for an additional 24 h at 371C, then harvested for phenotypic analysis by flow cytometry and Western blot.
Flow cytometric analysis
For phenotypic analysis, CaD1, Tg1-1, MCA-26 and MCA-26neu tumor cells were stained for 30 min on ice with anti-neu Ab (Ab-4, 2 mg/ml). DCs, DC pLpA and DC neu cells were incubated with Abs specific for H-2K 
Western blot analysis
Neu expression in Tg1-1, MCA-26neu and DC neu cells was assessed using Western blots. Briefly, cell protein extracts were prepared from these cells using extraction buffer containing 125 mM tris (hydroxymethyl) aminomethane, 0.05% sodium dodecyl sulfate and 10% b-mercaptoethanol and harvested from the supernatant after centrifugation at 1000 g for 5 min. The supernatants containing the protein samples were electrophoresed through 7.5% gels and transferred onto nitrocellulose papers; blots were blocked using PBS containing 5% nonfat milk and incubated with the anti-neu Ab (Ab-3; 5 mg/ ml) followed by horseradish peroxidase-conjugated goat anti-mouse IgG Ab. 26 Detection of HER-2/neu was accomplished by using enhanced chemiluminescence reagent (New England Nuclear Life Science Products, Boston, MA, USA).
RNase protection assay
DCs were subjected to RNase protection assays 60 using a commercial kit (RiboQuant Multi-Probe kit; Pharmingen) in accordance with the manufacturer's instructions. RNA was extracted from the cells using a commercial kit (Pharmingen). 33 P-uridine triphosphate (UTP)-labelled probes (Amersham Canada Ltd, Oakville, Ontario, Canada) were generated by in vitro transcription of cytokine/chemokine-related multi-probe template sets (Pharmingen) using T7 RNA polymerase. Labeled probes were first purified by phenol-chloroform extraction and ethanol precipitation with their counts adjusted to 3 Â 10 5 counts per minute (c.p.m.)/ml, then hybridized to RNA samples (5 mg each). Reaction samples were subsequently digested with RNase, followed by Proteinase K treatment and phenol-chloroform extraction. Following ethanol precipitation, the protected samples were resuspended in 1 Â loading buffer and separated on 5.7% acrylamide-bisacrylamide urea gels. Gels were dried and exposed to a phosphorimager screen and by autoradiography. Results were visualized and the relative expressions of cytokine and chemokine encoding mRNA were quantified with Quantity One software (BioRad, Hercules, CA, USA).
Cytokine expression
For evaluation of the type of immune response, FVB/N mice were vaccinated twice subcutaneously (s.c.) with 1 Â 10 6 DC neu cells and vaccinated intra-muscularly (i.m.) with 100 mg pcDNAneu DNA, respectively. Draining popliteal lymph node were harvested 3 days after the last immunization. LN T cells were cultured with irradiated Tg1-1 tumor cells (20 000 rad) in DMEM plus 10% FCS and IL-2 (20 U/ml) for 1 and 3 days. T-cell as well as DC culture supernatants were assayed for expression of IL-4, IL-6, TNF-a and IFN-g using cytokine ELISA kits (PharMingen), respectively, according to the manufacturer's instructions. 30 T cell and Tg1-1 tumor cell proliferation assays Naive T cells were prepared from FVB/N mouse splenocytes by using nylon wool columns.
30 CD4 + 25 + Tr cells were further purified from these naive T cells by using anti-CD25 microbeads. 31 In all experiments, 90-95% of these cells were positive for both CD4 and CD25 markers (data not shown). In T-cell proliferation assay, naive T cells (0.1 Â 10 6 cells per well) were incubated with DCs (0.2 Â 10 5 cells per well) and its dilutions plus the anti-CD3 Ab (1 mg/ml) in the absence or presence of CD4 + 25 + Tr cells or anti-IL-6 Ab (10 mg/ml, BD Pharmingen) in the round bottom 96-well plates for 2 days. T-cell proliferation was measured using an overnight 3 [H]thymidine (1 mCi/ml; Amersham, Oakville, Ontario, Canada) uptake assay (1 mCi/well). The levels of 3 [H]thymidine incorporation into the cellular DNA were determined by liquid scintillation counting. 30 Tumor cell proliferation assay using 2 Â 10 4 Tg1-1 or CaD1 tumor cells mixed with sera from immunized mice (1:50) were plated in a 96-well tissue culture plate incubated at 371C. 61 Normal mouse sera and anti-neu Ab were used as negative and positive controls, respectively. After 5 days, cell proliferation was measured by MTT (3-(4,5-dimethyl-2-thiozolyl)-2,5-diphenyl-2H-tetrazolium bromide) assays using CellTiter 96 Non-radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA). Plates were read at 595 nm using a Bio-Rad Model 3550 microplate reader. Inhibition was calculated by (blank absorbance-experimental absorbance)/(blank absorbance-background absorbance) Â 100, where blank values referred to wells with no serum added and background values referred to wells with no cells added.
Antibody responses
FVB/N and BALB/c mice were vaccinated s.c. with 1 Â 10 6 DC neu cells and i.m. with 100 mg pcDNAneu DNA
Comparing HER-2/neu DNA and engineered DC vaccines T Chan et al once or twice with a 14-day interval, respectively. Sera were collected from mice 2 weeks after each treatment and diluted to 1:50 or 1:80. The presence of neu-specific antibodies was assayed using Tg1-1 tumor cells by flow cytometry and live-cell ELISA. 62 Isotype determinations were carried out using FITC-and peroxidase-conjugated anti-mouse IgG1 and IgG2a Abs, respectively.
Cytotoxicity assays
In cytotoxic T lymphocyte assay, red blood cell-depleted splenic lymphocytes from mice vaccinated with DC neu were co-cultured in 24-well plates with irradiated Tg1-1 cells (20 000 rad), using 5 Â 10 6 lymphocytes and 2 Â 10 5
Tg1-1 cells per 2 ml of DMEM plus 10% FCS. After 3 days, activated T cells were harvested by Ficoll-Paque density gradient centrifugation and used as effector cells against radiolabeled Tg1-1 or CaD1 target cells in a chromium-release assay. 26 Target cells (10 4 /well) were incubated for 8 h in triplicate cultures with effector cells at various E:T ratios. The percent-specific lysis was calculated using the formula: The spontaneous c.p.m. release in the absence of effector cells was less than 10% of specific lysis; maximal CPM release was obtained by adding 1% Triton X-100 to the cells.
In vivo cytotoxicity assay was also performed as previously described. 63 Briefly, FVB/N mice were immunized with DNA, DC neu or PBS twice 2 weeks apart. To generate differentially labeled target cells, splenocytes from naïve mice were incubated with either high (3.0 mM, CFSE high ) or low (0.6 mM, CFSE low ) concentrations of CFSE. The CFSE high cells were pulsed with the neu peptide, PDSLRDLSVF, and the CFSE low cells were pulsed with the LCM N protein irrelevant peptide, RPQASGVYM, 23 and washed extensively. Both CFSE high and CFSE low were coinjected intravenous (i.v.) at a 1:1 ratio in immunized mice, 6 days following the last immunization. At 16 h after injection, spleens were removed to analyze residual CFSE high and CFSE low target cells remaining in recipients' spleens by flow cytometry.
Vaccination of mice with DC neu
We also selected to immunize mice with s.c. and i.m. routes for administration of DCs and DNA, as they induced more efficient immune responses than i.v. or intraperitoneal (i.p.) administration of DCs 64, 65 and s.c. injection of DNA, 66, 67 respectively. For evaluation of tumor immunity, FVB/N and BALB/c mice were vaccinated s.c. with 1 Â 10 6 DC neu cells and i.m. with 100 mg pcDNAneu DNA twice with a 14-day interval, respectively. At 10 days subsequent to the vaccination or the boost, the mice (n ¼ 8 per group) were challenged by s.c injection of 3 Â 10 5 Tg1-1 and MCA-26neu tumor cells. Animal mortality and tumor growth were monitored daily for up to 60 days; mice with tumors greater than 12 mm average diameter were euthanized for humanitarian reasons. For evaluation of tumor prevention, FVBneuN transgenic mice (n ¼ 10 per group) at the age of 2 and 4 months were vaccinated s.c. with 1 Â 10 6 DC neu cells and vaccinated i.m. with 100 mg pcDNAneu DNA at a 1-month interval, for a total of three vaccinations.
Spontaneous breast tumor development was monitored weekly for up to 12 months. Tumor-free time curves were recorded when the first tumor of each mouse reached a palpable size of 3 mm in diameter. All tumors were confirmed by routine histological examination.
Statistical analyses
Statistical analyses were carried out using Prism software (GraphPad Software, Inc., San Diego, CA, USA) to form Kaplan-Meier survival chart and to perform Log rank test to compare mouse survival and tumor development between groups. Student's t-tests were performed to determine the significance of differences between groups. P-values o0.05 were considered significant.
